Microsaic Systems plc Microsaic to Exhibit at BioProcess International
13 September 2017 - 4:01PM
RNS Non-Regulatory
TIDMMSYS
Microsaic Systems plc
13 September 2017
13 September 2017
Microsaic Systems plc
("Microsaic", "Microsaic Systems" or the "Company")
Microsaic to Exhibit at BioProcess International, Boston
Microsaic Systems plc (AIM: MSYS), the developer of chip-based
mass spectrometry ("MS") instruments will be exhibiting at
BioProcess International ("BPI"), September 25-28 2017, at booth
200 at the Hynes Convention Centre, Boston, MA, USA.
BPI is the largest bioprocessing event in the world, bringing
together the biggest global names in bioprocessing science and
technology that are focused on accelerating promising biologics to
market.
Bioprocessing is an essential process for producing and
purifying intact and functional biological material from cells.
Microsaic's strategy is to work with the key providers of
bioprocessing equipment, in particular those companies involved in
biologic purification, to apply its MS instrument (the 4000 MiD(R))
for the detection of therapeutic proteins and antibodies.
The benefits of Microsaic's point-of-use MS technology, in
combination with its patented innovation for on-line desalting,
make it a powerful on-line and at-line confirmatory analysis tool
with multiple points of entry in upstream and downstream
bioprocessing. This enables important time and cost savings of
making the biologics, as analysis times can be reduced from days or
even weeks to minutes.
MS is a powerful technique which allows the effective
implementation of "QbD" (Quality by Design), a key industry and
regulatory driver for current and future production of
biologics.
Glenn Tracey, Microsaic's Chief Operating Officer,
commented:
"We see significant opportunities for Microsaic's MiD
instruments integrated into multiple areas of bioprocessing, to
enhance efficiency and quality. Bioprocessing is a rapidly growing
market, as indicated by the growth in biologics; 8 of the top 10
drugs sold in 2015 were biologics with multibillion dollar annual
sales and their market share, in terms of drugs in development and
on the market, continues to grow. Our aim is to develop
partnerships with key providers of bioprocessing equipment in this
increasingly profitable area that has a strong market-pull for
MS."
Enquiries:
Microsaic Systems plc
Glenn Tracey, COO
Bevan Metcalf, FD +44 (0) 1483 751577
N+1 Singer (Nominated Adviser
& Broker)
Shaun Dobson
Liz Yong +44 (0)20 7496 3000
Citigate Dewe Rogerson
(Financial PR)
Mark Swallow
Shabnam Bashir +44 (0)20 7638 9571
About Microsaic Systems
Microsaic Systems plc (AIM: MSYS) is a high technology company
developing chip-based, bench-top and point-of-analysis mass
spectrometry ("MS") instruments that are designed to improve the
efficiency of pharmaceutical R&D. The Company is working with
established global life science companies to co-develop new
solutions to improve productivity in the development of small
molecule and novel biologic (peptides, antibodies) medicines. MS is
a powerful method of analysis to enable earlier decision making
relating to product identification, purity and bioactivity, and is
the analytical technique of choice for biochemists across many
industry sectors.
Microsaic's core product, the 4000 MiD(R), is one of the
smallest MS systems in the world, retaining the functionality of
larger conventional MS systems, is easier to use by
non-specialists, consumes less energy and has lower running costs.
For more information, please go to www.microsaic.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZLLFFDKFEBBD
(END) Dow Jones Newswires
September 13, 2017 02:01 ET (06:01 GMT)
Microsaic Systems (LSE:MSYS)
Historical Stock Chart
From Apr 2024 to May 2024
Microsaic Systems (LSE:MSYS)
Historical Stock Chart
From May 2023 to May 2024